期刊论文详细信息
Biomarker Research
MicroRNAs as promising biomarkers in cancer diagnostics
Prasun J Mishra1 
[1] US Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Laboratory of Cancer Biology & Genetics, Bethesda, MD 20892, USA
关键词: Metastasis;    miRNA variant;    Clear cell renal cell carcinoma;    Osteosarcoma;    Colorectal cancer;    Tumor microenvironment;    Exosomic;    Circulating microRNAs;    Polymorphism;    miRSNP;    SNPs;    Diagnostics;    Biomarker;    microRNA;   
Others  :  1084169
DOI  :  10.1186/2050-7771-2-19
 received in 2014-08-29, accepted in 2014-09-22,  发布年份 2014
PDF
【 摘 要 】

Cumulating data suggest that small noncoding-RNAs such as microRNAs (miRNAs) can be utilized as potential biomarkers for the diagnosis and prognosis of a variety of diseases such as cancer, neurological disorders, cardiovascular disease and Type-II diabetes, etc. MiRNAs can be utilized not only for monitoring of treatments but also for patient stratifications. The Tenth Annual miRNA as Biomarkers and Diagnostics conference, 2014, organized in Boston, MA, was primarily focused on recent advancements in the field of miRNA in the early detection of disease, monitoring tumor growth/progression and its potential for precision medicine. This article summarizes findings presented in the miRNA biomarker as cancer diagnostics session. The overarching projections from this and other sessions were that miRNAs are now well established as regulators of tumorigenesis and can be utilized not only as potential biomarkers for the diagnosis and prognosis of a disease but also are useful in patient stratifications and treatment response.

【 授权许可】

   
2014 Mishra; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150113154616300.pdf 133KB PDF download
【 参考文献 】
  • [1]Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866.
  • [2]Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99(24):15524-15529.
  • [3]Mishra PJ, Merlino G: MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 2009, 119(8):2119-2123.
  • [4]Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR: A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 2007, 104(33):13513-13518.
  • [5]Mishra PJ, Bertino JR: MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009, 10(3):399-416.
  • [6]Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, Merlino G, Ju J, Bertino JR: MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One 2009, 4(12):e8445.
  • [7]Mishra PJ: The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins. Pharmacogenomics 2012, 13(12):1321-1324.
  • [8]Alt FW, Kellems RE, Bertino JR, Schimke RT: Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 1978, 253(5):1357-1370.
  • [9]Mishra PJ: MicroRNA polymorphisms: a giant leap towards personalized medicine. Pers Med 2009, 6(2):119-125.
  • [10]Challagundla KB, Fanini F, Vannini I, Wise P, Murtadha M, Malinconico L, Cimmino A, Fabbri M: microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. Expert Rev Mol Diagn 2014, 14(5):565-574.
  • [11]Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, Caligiuri MA, Nana-Sinkam P, Perrotti D, Croce CM: MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012, 109(31):E2110-E2116.
  • [12]Sempere LF, Korc M: A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol Biol 2013, 980:43-59.
  • [13]Sempere LF: Recent advances in miRNA-based diagnostic applications. Expert Rev Mol Diagn 2012, 12(6):557-559.
  • [14]Ju J, Jiang J, Fesler A: miRNA: the new frontier in cancer medicine. Future Med Chem 2013, 5(9):983-985.
  • [15]Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J: Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010, 9:96. BioMed Central Full Text
  • [16]Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, Burke S, Shroyer K, Ju J: Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer 2011, 10(4):340-347.
  • [17]Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J: Prognostic significance of miR-194 in endometrial cancer. Biomark Res 2013, 1:12. BioMed Central Full Text
  • [18]Zhai H, Song B, Xu X, Zhu W, Ju J: Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene 2013, 32(12):1570-1579.
  • [19]Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW: A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 2011, 121(2):809-820.
  • [20]Weng L, Wu X, Gao H, Mu B, Li X, Wang JH, Guo C, Jin JM, Chen Z, Covarrubias M, Yuan YC, Weiss LM, Wu H: MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 2010, 222(1):41-51.
  • [21]Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, Wu JJ, Ruel NH, Wilczynski SP, Gao H, Covarrubias M, Figlin RA, Weiss LM, Wu H: Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012, 7(5):e35661.
  • [22]Mishra PJ: Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2014, 14(8):917-919.
  文献评价指标  
  下载次数:9次 浏览次数:8次